Cargando…
Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study
INTRODUCTION: Belimumab is a recombinant human immunoglobulin G1λ monoclonal antibody indicated as an intravenous (IV) 10 mg/kg and subcutaneous (SC) 200-mg dose for the treatment of systemic lupus erythematosus (SLE). Belimumab 10 mg/kg IV has been approved for the treatment of patients with SLE in...
Autores principales: | Meng, Xianmin, Wang, Qianqian, Wu, Shunquan, Pu, Di, Zhang, Amber, Fang, Sun, Zhou, Xuan, Lu, Hongzhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572285/ https://www.ncbi.nlm.nih.gov/pubmed/34554352 http://dx.doi.org/10.1007/s40744-021-00366-0 |
Ejemplares similares
-
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017) -
An open-label trial of alsuma auto-injector for migraine
por: Ramos, E, et al.
Publicado: (2013) -
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018) -
A 6-month open-label extension study of the safety and efficacy of
subcutaneous belimumab in patients with systemic lupus
erythematosus
por: Doria, A, et al.
Publicado: (2018) -
Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
por: Yapa, S Wickramaratne Senarath, et al.
Publicado: (2016)